Tag: undruggable cancer targets
Novartis strikes a $1.9B partnership with Antares Therapeutics to tackle “undruggable” cancer targets.
Novartis has entered into a strategic collaboration and license agreement with Antares Therapeutics to discover and develop next-generation small molecule oncology treatments. The transaction...